We are leaders in
CRISPR/Cas9 gene targeting. We have completed over 100 CRISPR/Cas9 projects including knockouts, reporter and point mutant knockins and targeted transgenics. Our
fees are low, our
wait times are short and our
success rates are high. New transgenic and targeted mice that we have created are featured in over 270
publications since 2004. We are supported by the
Case Western Reserve University School of Medicine the
Case Comprehensive Cancer Center, the
Clinical and Translational Science Collaborative,
the Research Institute for Children's Health and by grants from the NIH, the Cystic Fibrosis Foundation and JobsOhio.
We are a component of the
FIND Pipeline, which translates gene-directed approaches into therapies for inherited disease.